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ABSTRACT
Thickening of the airway smooth muscle is central to bronchial hyperreactivity. We have 
shown that the sphingosine analog AAL-R can reverse pre-established airway 
hyperreactivity in a chronic asthma model. Since sphingosine analogs can be 
metabolized by sphingosine kinase 2, we investigated whether this enzyme was 
required for AAL-R to perturb mechanisms sustaining airway smooth muscle cell 
proliferation. We found that AAL-R pre-treatment reduced the capacity of live airway 
smooth muscle cells to use oxygen for oxidative phosphorylation and increased lactate 
dehydrogenase activity. We also determined that sphingosine kinase 2 was upregulated 
in airway smooth muscle cells bearing the proliferation marker Ki67, relative to their 
Ki67-negative counterpart. Comparing different stromal cell subsets of the lung, we 
found that high sphingosine kinase 2 levels were associated with the ability of AAL-R to 
inhibit metabolic activity assessed by conversion of the tetrazolium dye MTT. Knock 
down or pharmacologic inhibition of sphingosine kinase 2 reversed the effect of AAL-R 
on MTT conversion, indicating the essential role for this kinase in the metabolic 
perturbations induced by sphingosine analogs. Our results support the hypothesis that 
increased sphingosine kinase 2 levels in proliferating airway smooth muscle cells could 
be exploited to counteract airway smooth muscle thickening with synthetic substrates.
KEYWORDS
Asthma, sphingolipids, metabolism, AAL-R, FTY720 
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INTRODUCTION
Asthma is characterized by a thickening of the airway smooth muscle (ASM), which 
contributes prominently to airway narrowing (1). There is no existing pharmacological 
treatment specifically designed to impede ASM thickening in asthma, although 
corticosteroid can accelerate its resorption under specific conditions (2, 3). Both 
hyperplasia and hypertrophy of ASM cells are suspected to contribute to asthma 
pathogenesis (4). In vitro, ASM cells from asthmatics display a hyperproliferative and a 
hypersecretory phenotype (5, 6). Moreover, a number of studies have documented, at 
least in the distal airways, that cellular alterations compatible with heightened oxidative 
phosphorylation are associated with ASM enlargement, including increased 
mitochondrial numbers, mass, and oxygen consumption (7, 8). 
Of critical importance is the notion that enhanced mitochondrial functions are required to 
sustain instrumental aspects of tissue hypertrophy such as protein synthesis (9) and 
proliferation (10). Interfering with mitochondrial functions was shown to alleviate 
vascular smooth muscle hyperproliferation in the context of pulmonary hypertension (11) 
and oxidative phosphorylation is increased during stromal cell proliferation (12). It is thus 
conceivable that dysregulating energy metabolism is ASM cells could produce salutary 
effects in the context of asthma.
Increasing evidence obtained in the context of oncology suggest that synthetic 
sphingosine analogs can act through SPHK2 -dependent and -independent pathways to 
hamper cellular accumulation (13, 14). We recently demonstrated that a sphingosine 
analog, as well as substrate for SPHK2, could reverse airway smooth muscle thickening 
Page 3 of 38  AJRCMB Articles in Press. Published on 27-June-2019 as 10.1165/rcmb.2018-0397OC 
 Copyright © 2019 by the American Thoracic Society 
in experimental asthma; and that sub-toxic concentrations of this agent could induce 
ASM cell cytostasis in vitro (15). Nevertheless, the mechanisms underlying the 
propensity of SPHK2 substrates to impact ASM thickening remain unclear.
In this study, we determined that the SPHK2 substrate - AAL-R – causes metabolic 
alterations that precede the reduction of ASM cell accumulation in vitro. These include 
the alteration of overall oxidoreductase activity, the impairment of oxidative 
phosphorylation, and the enhancement of lactate dehydrogenase activity.  Importantly, 
we found that SPHK2 expression was increased in ASM cells bearing the proliferation 




Human primary ASM cells (CC-2576; Lonza, Walkersville, MD) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (unless 
otherwise indicated), non-essential amino acids and 1% penicillin/streptomycin, and 
plated at a density of 1.5x104 cells / cm2. Human primary epithelial cells obtained from a 
normal patient’s biopsy (Chakir laboratory) were characterized and cultured as 
described (16) and plated at a density of 2.5x104 cells / cm2. Human primary arterial 
endothelial cells (302-05a, Cell applications, San Diego, CA) were cultured in 
endothelial cell growth medium (Lonza, CC-3202) and plated at a density of 2.5x104 
cells / cm2. Primary hTERT-immortalized ASM cells from asthmatics were cultured as 
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described (5). Cells were used at passages 3 to 8. Crystal violet (17), BrdU, MTT, LDH 
activity and JC-10 assays, as well as p21 western blot, were performed according to 
manufacturer’s instruction (described in supplementary material).
Reagents
AAL-R and SLM6031434 were graciously provided by Hugh Rosen and Webster 
Santos, respectively. VPC 23019 was purchased from Tocris Bioscience (Oakville, ON, 
Canada), and recombinant human FGF-2 and TGF-1 were purchased from Peprotech 
(Montreal, QC, Canada).
siRNA transfection 
ASM cells were seeded at a density of 1.5 x 104 cells per cm2 and transfected using 
calcium-phosphate (18) for 24 h with 25 nM of mock siRNA (ThermoFisher) or SPHK2 
siRNA (s32285, ThermoFisher). Cells were incubated with VEH or increasing 
concentrations of AAL-R for 24 h for the MTT assay; with VEH or 1 µM AAL-R for 5 h for 
lipid quantification using liquid chromatography tandem-mass spectrometry as described 
(15). SPHK2 levels were assessed by western blot (Polyclonal, Proteintech) (described 
in supplementary material).
Flow cytometry
SPHK2 immunoreactivity on ASM, epithelial and endothelial cells was assessed as 
described in supplementary material. ASM surface expression of GLUT1 (polyclonal, 
Novus Biologicals) was measured after a 24 h incubation with 1 µM AAL-R. Apoptosis 
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was assessed after 72 h incubation with AAL-R 1, 5 and 10 µM using Pacific Blue 
Annexin V (Biolegend, San Diego, CA). 
Mitochondrial content and activity
Mitochondrial DNA quantification was assessed by quantitative polymerase chain 
reaction (qPCR) as described by Rooney et al. (19) and further detailed in 
supplementary material. Mitochondrial respiration was measured in intact ASM cells 
incubated in complete DMEM media with VEH or 1 µM AAL-R for 24 h, using the 
Oxygraph-2K (OROBOROS Instruments, Innsbruck, Austria) according to variations of 
published methods (20, 21). See supplementary material for the detailed protocol. 
Statistical analyses
Data were expressed using averages  SEM. After verifying homogeneity of variances 
and the assumption of normality, unpaired T tests or ANOVA were performed. Post hoc 
analyses were performed using the Sidak correction. When necessary, data were log 
transformed prior to performing parametric tests. Data of oxygen consumption for 
mitochondrial respiration was evaluated using a RM-ANOVA followed by Fischer 
multiple comparison tests. All tests were performed with the Prism v. 6.01 software 
(GraphPad Software, Inc.). The significance of p was set at 0.05 for all the tests.
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RESULTS
Metabolic alterations induced by AAL-R precede cytostasis
Increasing evidence supports that alteration of energy metabolism by sphingosine 
analogs contribute to inhibit proliferation (13). We observed that AAL-R, at a 
concentration of 1 µM, diminished the tetrazolium dye MTT reduction to formazan by 38 
% after 24 h of incubation compared to cells incubated with the vehicle (Fig 1A), 
suggesting a decreased cell number or an hampered metabolic activity. We determined 
that accumulation of ASM cells, measured using the crystal violet staining, was not 
decreased by AAL-R at that time point (Fig 1B), showing that the metabolic activity 
rather than the accumulation of cells was in play at this early time point. In agreement 
with our previous results (15), AAL-R significantly altered BrdU incorporation relative to 
vehicle at 48 h (Fig 1C), which occurred in absence of striking accumulation of Annexin 
V-positive cells over a 72 h incubation period (Fig 1D). Thus, it appears that a 
concentration of AAL-R sufficient to cause cytostasis, but not apoptosis, rapidly impacts 
on determinants of oxidoreductase activity in ASM cells. 
AAL-R interferes with oxidative phosphorylation and promotes lactate 
dehydrogenase activity
Since MTT reduction depends on oxidoreductase activity, which can involve both 
mitochondrial-dependent and -independent events, we determined if AAL-R impacted on 
the ability of proliferating ASM cells to utilize oxygen (Fig 2). We first compared, as a 
surrogate for mitochondrial numbers per cell, the relative amount of the 
tRNA(Leu(UUR)) mitochondrial gene vs the β2-microglobulin nuclear gene between 
experimental conditions. We found that AAL-R did not reduce the tRNA(Leu(UUR)) / β2-
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microglobulin ratio, which provides evidence that reduced numbers of mitochondria per 
cell did not account for the altered MTT conversion (Fig 2A). However, we determined 
that routine oxygen consumption was reduced by nearly 15% as a result of the altered 
capacity to use oxygen in order to generate ATP (OXPHOS; 27% decrease), rather than 
by increasing proton leak (not different from VEH) (Fig 2B). This was accompanied by a 
shift towards a glycolytic metabolism that was evidenced by an increased cell surface 
expression of GLUT1 (Fig 2C) and an increased LDH activity (Fig 2D). Consistent with 
increased markers of glycolysis, we determined that AAL-R increased mitochondrial 
membrane potential (Fig 2E) measured by incorporation of the JC-10 dye (22). We did 
not observe a modulation of p21 levels in response to AAL-R (Fig 2F and Fig E1), 
indicating that it did not operate by influencing nuclear targets of SPHK2 products. 
Together, these results support the hypothesis that AAL-R mitigates energy metabolism 
in ASM cells.
Proliferative ASM cells are susceptible to AAL-R-induced inhibition of MTT 
conversion
Most sphingosine analogs are preferentially phosphorylated by SPHK2, compared to 
SPHK1 (22). Since proliferation likely contributes to ASM thickening in asthma (4, 5, 23), 
we assessed the immunoreactivity for SPHK2 in ASM cells bearing the proliferation 
marker Ki67 (Fig 3). Ki67-positive ASM cells showed a more than twofold increase in 
SPHK2 immunoreactivity compared to their Ki67-negative counterparts (Fig 3A-B), 
suggesting that proliferating ASM cells might feature an enhanced sensitivity to SPHK2 
substrates. We thus tested the impact of AAL-R under two culture conditions known to 
promote ASM cell proliferation in vitro, namely 10% FBS (24, 25), and combined 
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FGF2/TGF- (17); as well as in ASM cells cultured in complete medium containing 1% 
FBS into which they do not expand (Fig 3C). We found MTT conversion to be enhanced 
regardless of the anabolic stimulus compared to the cells cultured in 1% FBS. Moreover, 
AAL-R decreased the conversion of MTT by nearly 40% under both anabolic stimuli 
compared to vehicle. Of note, AAL-R marginally affected MTT conversion in cells 
incubated with 1% FBS, suggesting that proliferative cells featuring high SPHK2 levels 
are susceptible to AAL-R-induced metabolic alterations.
AAL-R preferentially affects cells with high SPHK2 levels 
Phosphorylatable sphingosine analogs can be delivered in the airways of mice with 
limited histological impacts (26, 27). Yet, we recently showed that the dysregulated ASM 
compartment, as seen in the context of asthma, resorbs in the presence of 
phosphorylatable sphingosine analogs such as AAL-R (15), indicating that the ASM 
features elements of sensitivity to this type of agents. We thus compared the expression 
of SPHK2 in ASM cells and other prevalent stromal cell subsets of the lung, namely 
endothelial and epithelial cells. We found that immunoreactivity for SPHK2 is twice 
higher in ASM cells compared to epithelial or endothelial cells (Fig 4A-B). In line with 
the pattern of SPHK2 expression of ASM cells, epithelial and endothelial cell lines, we 
observed that AAL-R potently inhibited the conversion of MTT by 45% in ASM cells, 
while having limited effects in endothelial and epithelial cell lines (Fig 4C). These results 
suggest that stromal cells with high SPHK2 levels are susceptible to metabolic 
perturbations induced by SPHK2 substrates. We also confirmed that AAL-R reduced 
MTT conversion in ASM cells from asthma patients (Fig 4D).
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AAL-R-induced alteration of MTT conversion depends on SPHK2
To determine whether the impact of AAL-R on MTT conversion is dependent on SPHK2, 
we employed complementary strategies. We first demonstrated that low concentrations 
of SLM6031434, a SPHK2 inhibitor known to interfere with the phosphorylation of 
sphingosine analogs in vitro (28), rescued proliferating ASM cells from AAL-R-induced 
inhibition of MTT conversion (Fig 5A). Similarly, the lack of effect of AAL-R was 
recapitulated by knocking down SPHK2 with siRNAs (Fig 5B). In line with the contention 
that changes in the kinetics of AFD-R accumulation (the phosphorylated form of AAL-R) 
shall critically affect the impact of AAL-R on ASM cell function, we determined that 
SPHK2 knock down reduced the AFD-R to AAL-R ratio by nearly 50% (Fig 5C). Of note, 
we also confirmed the efficacy of siRNAs to reduce the content of SPHK2 (Fig 5D).
ASM cells express S1P1, S1P2, and S1P3 receptors (15). Because AFD-R can bind to all 
S1P receptors except S1P2 (29), we investigated their involvement in the AAL-R-
mediated effects (Fig 5E). As expected, AAL-R diminished MTT conversion in 
proliferating cells, compared to vehicle. Arguing against a prominent role for 
endogenous/medium-containing S1P acting on S1P1 and S1P3 for FBS-driven 
enhancement of MTT conversion, we found that the dual S1P1 and S1P3 antagonist 
VPC23019 (10µM) had no effect on MTT conversion in absence of AAL-R, when 
compared to vehicle. Moreover, VPC23019 failed to alleviate the AAL-R-induced 
alteration of MTT conversion, refuting S1P receptors involvement. 
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DISCUSSION 
The ASM is at the core of asthma symptoms and its thickening results from the 
perpetual stimulation with numerous anabolic stimuli including growth factors, 
spasmogens, and immune modulators (30, 31). The persistent reduction of ASM 
thickening associated with the long-term benefits of bronchial thermoplasty indicates 
that punctual interventions directed against the ASM bear therapeutic potential (32-34). 
We showed that the SPHK2 substrate AAL-R potently reversed airway 
hyperresponsiveness in a corticosteroid-resistant model of asthma and induced human 
ASM cell cytostasis in vitro (15), suggesting that SPHK2 could be a therapeutically-
amenable target for interfering with ASM enlargement. 
The current study furthers this contention by unraveling the preferential efficacy of AAL-
R to alter energy metabolism when ASM cells are under anabolic conditions. For that 
matter, we found that ASM cells undergoing proliferation upregulate SPHK2 and that 
pulmonary stromal cell subsets with the highest levels of SPHK2 are more sensitive to 
metabolic perturbations induced by AAL-R. Critically, we demonstrate that knocking 
down or inhibiting SPHK2 makes AAL-R impotent at interfering with the activity of ASM 
cells, showing that beneficial effects depend on SPHK2. 
If SPHK2 is increased in ASM cells under anabolic conditions, then why hasn’t it come 
out in the omic studies of asthma? In our view, the most important factor masking the 
relationship between SPHK2 and asthma is that mild, but not severe SPHK2 
overexpression sustains hyperproliferation (35). These findings are consistent with our 
own observation that ASM cells upregulate SPHK2 by merely twofold, when 
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proliferating. SPHK2 could thus be required for altering anabolic responses without 
affecting quiescent cells. In line with the usual caveats of omic studies performed on 
whole tissue samples, SPHK2 is not equally expressed in the different cell types of the 
lung, which is confirmed by our in vitro findings exposing unequal SPHK2 
immunoreactivity between ASM cells, endothelial and epithelial cells. Although our study 
was performed with a limited number of cell lines, our results clearly demonstrate that 
AAL-R can alter MTT signal in ASM cells from asthma patients; and that cell lines with 
the highest levels of SPHK2 are the most susceptible to the metabolic perturbations 
induced by a SPHK2 substrate. Together with our previous in vivo findings showing that 
AAL-R does not cause aversive effects in the airways while reversing 
hyperresponsiveness (15), the results of the current study argue that mild 
overexpression of SPHK2 in ASM cells under anabolic conditions increases their 
susceptibility to AAL-R-induced metabolic perturbations.
This notion is also corroborated by the fact that SPHK2 substrates with the intrinsic 
propensity to rapidly accumulate into cells are the most potent at inhibiting MTT 
conversion and/or cell accumulation (13, 36, 37). In the same line of thoughts, the 
sensitivity to rapidly-phosphorylated SPHK2 substrates correlates with the level of 
SPHK2 expression in cancer cells (13). The correlation between SPHK2 expression and 
sensitivity to SPHK2 substrates also aligns with our observation that a partial knock 
down of SPHK2, which leads to a 50% decrease of the AFD-R to AAL-R ratio, 
abrogated the impact of low micromolar concentrations of AAL-R on MTT conversion. In 
addition, concentrations of the SPHK2 inhibitor SLM6031434 lower than its documented 
IC50 were sufficient to halt AAL-R-induced perturbation of MTT conversion (28). 
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Therefore, our study strengthens the notion that asthma-related increase of SPHK2, or 
alternatively that means of promoting SPHK2 expression in the airway smooth muscle, 
could serve as a basis to counteract asthma with SPHK2 substrates.
The current study also supports the contention that the ability of sphingosine analogs to 
interfere with ASM thickening likely not involve the activation/reactivation of protein 
phosphatases. Indeed, it was shown that AAL-S, an isomer of AAL-R that is not a 
SPHK2 substrate, inhibited the development of experimental asthma by a mechanism 
involving the promotion of protein phosphatase activity, leading to the inhibition of 
inflammatory mediators release (38). Importantly, intracellular accumulation of the non-
phosphorylated form of sphingosine analogs was also shown to promote protein 
phosphatase activity in cancer cell lines, which led to their decreased accumulation 
through the inhibition of nutrient intake (37). For that matter, it is increasingly clear that 
sphingosine analogs poorly metabolized by SPHK2 preferentially promote protein 
phosphatase activity, when compared to rapidly-metabolized substrates, like AAL-R 
(37). Our finding that AAL-R loses its ability to interfere with ASM cell metabolism when 
SPHK2 is knocked down, combined to no inhibition of cell surface expression of GLUT1, 
argue that the mechanisms of action likely not rely on the promotion of protein 
phosphatase activity. 
Although cells deficient for SPHK2 were documented to display an altered mitochondrial 
function (39), we were not surprised that SPHK2 knock down or pharmacological 
inhibition did not impact on basal MTT conversion. In fact, it appears that mitochondrial 
impacts of SPHK2 knock down are highly dependent on the system, with fully knocked 
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out cardiomyocytes displaying a mere 20% inhibition of complex IV-associated O2 
consumption, and partial SPHK2 knock down in Hela cells yielding a more than 50% 
inhibitory effect (39). Our results suggest that the metabolic effects of SPHK2 substrates 
exceed the impact of SPHK2 modulators in perturbing mitochondrial functions under the 
current experimental conditions.
Our study indicates that the mechanisms of action of synthetic SPHK2 substrates 
overlap with some of the functions of the endogenous substrate (sphingosine). Indeed, 
we determined that the decreased oxygen consumption caused by AAL-R led to 
mitochondrial membrane hyperpolarity. Since endogenous S1P inhibits the 
depolarisation of the mitochondrial membrane in response to hypoxic episodes (40), it is 
possible that the phosphorylated form of AAL-R acts as an intracellular S1P mimic in 
order to prevent the loss of mitochondrial membrane potential and thus prevent cell 
death. Although this theory will require further investigation, we determined that AAL-R 
induced an upregulation of GLUT1 at the cell surface, an event that also confers 
protection against apoptosis in situations where oxidative metabolism is altered (41, 42). 
Altogether, our results support the hypothesis that SPHK2 substrates are modulators of 
energy metabolism, and evidence that they trigger compensatory mechanisms usually 
associated with hypoxia that likely prevent mitochondrion-associated cell death.
CONCLUSION
Although reversing the thickening of the ASM is likely to improve asthma in a majority of 
patients, there is currently no clinically-approved pharmacological strategies that directly 
target the ASM. The task of identifying such strategy is made complex by the subtle 
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phenotypical changes seen in ASM cells from patients in vitro, by the fact that 
mechanisms promoting and sustaining ASM thickening are numerous, interacting, and 
thus not finite. Our findings have unravelled that SPHK2 levels are increased in ASM 
cells subjected to anabolic stimuli. In line with the central role of sphingolipids in 
regulating cell fate and metabolism, our study supports the concept that this 
upregulation could be employed to interfere with the anabolically-skewed profile of the 
ASM in asthma.
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FIGURE LEGENDS 
Figure 1. A cytostatic concentration of AAL-R inhibits metabolic activity of ASM 
cells. Primary human ASM cells were incubated with vehicle (VEH) or AAL-R in 
complete media containing 10% FBS. A) A 24 h incubation with AAL-R (1 µM) 
decreased MTT conversion, which occurred B) without modulation of ASM cell 
accumulation. C) After 48 h of incubation, AAL-R (1 µM) reduced BrdU incorporation 
compared to the vehicle. D) These alterations occurred without significant induction of 
apoptosis over 72 h. n= 3-8, *: p<0.05 compared to VEH.   
Figure 2. AAL-R causes a shift towards glycolytic metabolism. A-B) Primary human 
ASM cells were incubated for 24 h with vehicle (VEH) or AAL-R (1 µM) in complete 
medium containing 10% FBS. AAL-R did not modify A) the ratio between genomic 
mitochondrial and nuclear housekeeping gene levels. B) Microoxymetry was performed 
in VEH and AAL-R-treated cells in order to derive O2 consumption associated with 
routine respiration, proton leak (state 4), OXPHOS (state 3) and maximal respiration, as 
described in methods. C) AAL-R (1 µM) led to the increase of GLUT1 and D) increased 
LHD activity after 24h. E) AAL-R increased JC-10 aggregates (red/green ratio) at 24h 
(FCCP 20 µM was used as a positive control) but F) had no impact on p21 expression at 
6 and 18h. n= 3-8, *: p<0.05 compared to VEH.  
Figure 3. SPHK2 overexpression in proliferative ASM cells sensitizes to inhibition 
of MTT conversion by AAL-R. A-B) Median fluorescence intensity (MFI) for SPHK2 is 
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higher in Ki-positive (Ki67+) proliferative primary human ASM cells compared to Ki-
negative (Ki-) cells. C) The impact of a 24 h exposure to vehicle (VEH) or AAL-R (1 µM) 
on MTT conversion was assessed in primary human ASM cells incubated in complete 
medium containing 10% FBS in FBS-free medium containing FGF-2 and TGF-β1 or in 
medium containing 1% FBS. n= 3-8, *: p<0.05 compared to VEH.
Figure 4. The inhibition of MTT conversion by AAL-R preferentially impacts on 
stromal cells with high SPHK2 expression. Primary human ASM, endothelial, 
epithelial and hTERT-immortalized ASM cells isolated from asthma patients were 
incubated in complete media containing 10% FBS. A-B) Flow cytometric analyses of 
SPHK2 immunoreactivity in proliferative primary human ASM cells compared to primary 
human endothelial cells and epithelial cells. C) ASM cells, but not endothelial and 
epithelial cells, show a decreased MTT conversion in response to AAL-R (1 µM) after 24 
h, compared to VEH. D) AAL-R (1 µM; 24 h) induces a decreased MTT conversion in 
hTERT-immortalized ASM cells from three different asthma patients (P1 to P3). n= 3-8, 
*: p<0.05. 
Figure 5. The inhibition of MTT conversion by AAL-R depends on SPHK2 but does 
not involve S1P receptors 1 to 3. Primary human ASM cells were incubated for 24 h 
with vehicle (VEH) or AAL-R (1 µM) in complete medium containing 10% FBS and A) 
the sphingosine kinase inhibitor SLM6031434. B) SPHK2 knockdown by siRNAs 
interferes with the loss of MTT signal induced by AAL-R when compared to mock-
transfected cells. C) Compared to mock-transfected cells, SPHK2 siRNA transfection 
reduced the phosphorylation of AAL-R to AFD-R. D) The efficiency of siRNAs against 
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SPHK2 was confirmed by western blots. E) The impact of a 24 h incubation with AAL-R 
(1 µM) on MTT conversion is not modified by the dual S1P1-3 antagonist VPC23019 (10 
µM). n= 3-8, *: p<0.05 compared to VEH. 
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R. A-B) Median fluorescence intensity (MFI) for SPHK2 is higher in Ki-positive (Ki67+) proliferative primary 
human ASM cells compared to Ki-negative (Ki-) cells. C) The impact of a 24 h exposure to vehicle (VEH) or 
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3-8, *: p<0.05 compared to VEH. 
80x93mm (600 x 600 DPI) 
Page 31 of 38  AJRCMB Articles in Press. Published on 27-June-2019 as 10.1165/rcmb.2018-0397OC 
 Copyright © 2019 by the American Thoracic Society 
 
Figure 4. The inhibition of MTT conversion by AAL-R preferentially impacts on stromal cells with high SPHK2 
expression. Primary human ASM, endothelial, epithelial and hTERT-immortalized ASM cells isolated from 
asthma patients were incubated in complete media containing 10% FBS. A-B) Flow cytometric analyses of 
SPHK2 immunoreactivity in proliferative primary human ASM cells compared to primary human endothelial 
cells and epithelial cells. C) ASM cells, but not endothelial and epithelial cells, show a decreased MTT 
conversion in response to AAL-R (1 µM) after 24 h, compared to VEH. D) AAL-R (1 µM; 24 h) induces a 
decreased MTT conversion in hTERT-immortalized ASM cells from three different asthma patients (P1 to P3). 
n= 3-8, *: p<0.05. 
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Figure 5. The inhibition of MTT conversion by AAL-R depends on SPHK2 but does not involve S1P receptors 1 
to 3. Primary human ASM cells were incubated for 24 h with vehicle (VEH) or AAL-R (1 µM) in complete 
medium containing 10% FBS and A) the sphingosine kinase inhibitor SLM6031434. B) SPHK2 knockdown by 
siRNAs interferes with the loss of MTT signal induced by AAL-R when compared to mock-transfected cells. C) 
Compared to mock-transfected cells, SPHK2 siRNA transfection reduced the phosphorylation of AAL-R to 
AFD-R. D) The efficiency of siRNAs against SPHK2 was confirmed by western blots. E) The impact of a 24 h 
incubation with AAL-R (1 µM) on MTT conversion is not modified by the dual S1P1-3 antagonist VPC23019 
(10 µM). n= 3-8, *: p<0.05 compared to VEH. 
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Metabolic adaptation of airway smooth muscle cells to a SPHK2 
substrate precedes cytostasis
Pascale Blais-Lecours1, Sofien Laouafa1, Christian Arias-Reyes1, Webster L. Santos2, 





BrdU, MTT, crystal violet, JC-10 and LDH activity assays
The Sigma-Aldrich colorimetric BrdU cell proliferation assay was used to quantify DNA 
synthesis as described by the manufacturer (Millipore Sigma, Oakville, ON, Canada). To 
quantify metabolic activity, cells were incubated in fresh media with 1 mM of tetrazolium 
dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Millipore Sigma) 
for 4 h at 37°C and formazan formation was measured by spectrophotometry at 540 nm 
after cell disruption with DMSO. Cell accumulation after AAL-R exposure was quantified 
by the crystal violet assay as described (1). Mitochondria membrane potential was 
measured using the JC-10 dye (Millipore Sigma, St-Louis, MO) following manufacturer’s 
instructions. Briefly, ASM cells were incubated in complete DMEM media with VEH or 
with 1 µM AAL-R for 24 h, or with 20 µM of the uncoupling agent FCCP for 10 min, prior 
to the incubation for 60 min with JC-10. The ratio of red fluorescence (polarized 
mitochondrial membrane) over green fluorescence (low membrane potential) was then 
measured by spectrophotometry. Lactate dehydrogenase (LDH) activity of ASM cells 
incubated in complete DMEM media with VEH or with 1 µM AAL-R for 24 h was 
measured using the colorimetric LDH Assay kit (Abcam, Cambridge, UK).
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Western blots
Cells were washed with PBS and lysed in buffer containing 1M HEPES, 4M NaCl, 100 
mM GDTA, 200 mM NaVO4, 1M NaF, 83.3 mM Na pyrophosphate, 500 mM Na beta 
glycerophosphate, protease inhibitor (complete Mini EDTA-free Protease Inhibitor 
Cocktail, Millipore Sigma), 10 mg/ml sodium deoxycholate, 1% NP40 and 10% SDS. 10 
to 15 µg of protein were loaded in 10% acrylamide gel for protein separation, transferred 
on a PVDF or nitrocellulose membrane and labeled overnight at 4°C with the rabbit anti-
SPHK2 antibody (Polyclonal, Proteintech), rabbit anti-p21 antibody (Monoclonal, Cell 
Signaling Technology) and the control protein antibody mouse anti--actin (Clone AC-
15, Sigma-Aldrich). Membranes were then incubated with horseradish peroxidase-
coupled anti-rabbit (Cell Signaling Technology) or anti-mouse (BD Biosciences) IgG, or 
with the IRDye 800 CW goat anti-rabbit IgG (LI-COR Biosciences), and signal was 
revealed with ECL Luminata Crescendo (EMD Millipore) and the ChemiDoc apparatus 
(Bio-Rad Laboratories, Mississauga, ON, Canada), or with the REVERT total protein 
stain (LI-COR Biosciences) and the Odyssey LI-COR apparatus (LI-COR Biosciences, 
Lincoln, Nebraska).
Flow cytometry
To quantify SPHK2 immunoreactivity, cells were grown to obtain a pool of 75% 
(proliferative) and 100% (non-proliferative) cell confluence, permeabilized with the Foxp3 
transcription factor staining buffer kit (eBioscience) and stained with primary antibodies 
raised against Ki67 (SolA15, eBioscience) and SPHK2 (Polyclonal, Proteintech, 
Rosemont, IL). Data were acquired using a FACS Diva-driven LSR Fortessa (BD, 
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Franklin Lake, NJ, USA) and analyzed with the FlowJo software (Tree Star Inc, Ashland, 
OR, USA). 
Assessment of mitochondrial content
ASM cells were incubated in complete DMEM media with VEH or with 1 µM AAL-R for 
24 h. DNA was extracted using the Qiaamp DNA mini kit (Qiagen, Toronto, ON, 
Canada) following manufacturer’s instructions. Relative expression of mitochondrial 
DNA (tRNA-Leu(UUR) on nuclear DNA (2-microglobulin, NC_000015.10) (2) was 
assessed using SsoAdvanced SYBR Green Supermix kit (Biorad, Hercules, CA). Both 
primer sets were validated and optimized using standard curves with efficiencies of 
100% and 99%, respectively. Melting curves were used to ensure the specificity of the 
PCR products. Relative quantification of mitochondrial DNA over nuclear DNA was 
calculated according to Pfaffl (3) and values were reported relative to VEH.
Assessment of mitochondrial activity
ASM cells were incubated in complete DMEM media with VEH or with 1 µM AAL-R for 
24 h, trypsinized, centrifuged and resuspended (0.2 million cells per ml) in the Oroboros 
apparatus at 37°C in complete DMEM. Cellular routine respiration is supported by 
exogenous substrates in culture media. Routine respiration includes oxygen 
consumption due to ATP synthesis (phosphorylating state or state 3, OXPHOS) and to 
proton leak (non-phosphorylating state or state 4). Following stabilization of routine, ATP 
synthesis was inhibited by oligomycin (2.5 M) to obtain state 4. State 3 was obtained 
by subtracting oxygen consumption in state 4 from routine respiration. The maximal 
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activity of the mitochondrial respiratory chain was assessed by titration with the 
uncoupling protonophore, carbonyl cyanide m-chlorophenylhydrazone factor (CCCP; 0.5 
M in 1 l/bolus, which transport protons thought the inner mitochondrial membrane). 





AAL-R VEH AAL-R VEH AAL-R VEH Ctrl Ctrl AAL-R VEH AAL-R VEH AAL-R VEH
18h 6h
1 2
Figure E1. AAL-R does not affect p21 levels. Primary human ASM cells were 
incubated for 6h or 18h with vehicle (VEH) or AAL-R (1 μM) in complete medium 
containing 10% FBS. Expression of p21 was assessed by western blot. Shown are 
complete membrane (top) and REVERT total protein stained blot (bottom) used to 
generate Figure 2F. The two different Ctrl samples are systematically loaded in all of our 
gels as quality controls.
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